AMCG Exhibits Quantum Sensing Cardiac Diagnosis at CES 2026

☞ Link to Article

Innovating Early Detection of Heart Disease through the Convergence of AI and Quantum Sensing 

Accelerating Global Market Expansion

[LAS VEGAS — Jan 7, 2026] – AMCG, a South Korean medical device specialist company, announced on the 7th (local time) that it has showcased its next-generation cardiac disease diagnostic solutions at 'CES 2026', the world’s largest consumer electronics and information technology (IT) exhibition currently held in Las Vegas.

During this exhibition, AMCG unveiled an innovative early-stage cardiac diagnosis system that combines Artificial Intelligence (AI) solutions with quantum sensing technology. This technology is expected to present a new paradigm in the field of preventive medicine. In particular, it is drawing the attention of medical professionals for its ability to significantly improve disease prediction accuracy in precision medicine.

The company is exhibiting two core products at the Yongin City Pa vilion within the KOTRA Korea Pa vilion.

The main highlights are the 'MCG-S', which has completed U.S. Food and Drug Administration (FDA) clearance, and the 'MCG-F', a new seated-type model scheduled for release this year.

Active business meetings with global buyers are continuing at the Korea Pa vilion within the Venetian Expo, where the exhibition is being held.

Seo Yong-seong, CEO of AMCG, stated, "Through our participation in CES 2026, we will promote our peerless technological capabilities to the world and accelerate the commercialization of our products in global markets, including the U.S., by expanding strategic partnerships."

[Financial News]